Pembrolizumab (immunotherapy Drug) in Combination with Guadecitabine and Mocetinostat (epigenetic Drugs) for Patients with Advanced Lung Cancer.
The purpose of this study is to test the safety of a combination of three drugs, pembrolizumab, guadecitabine and mocetinostat. Pembrolizumab is a drug given by vein and all patients will receive the same dose. Guadecitabine and mocetinostat will be given at different doses to find out what effects, if any, they have on treating your cancer and side effects.
Lung Cancer
DRUG: Pembrolizumab|DRUG: Guadecitabine|DRUG: Mocetinostat
number of patients with adverse events, events occurring on or after treatment on the first day of any study therapy will be summarized by dose cohort, toxicity term, CTCAE v4.0 grade, 1 year|response rate (Phase Ib), Tumor response will be assessed using RECIST 1.1. All responses must be confirmed on subsequent scan to be considered a true response., within 6 months of treatment
The purpose of this study is to test the safety of a combination of three drugs, pembrolizumab, guadecitabine and mocetinostat. Pembrolizumab is a drug given by vein and all patients will receive the same dose. Guadecitabine and mocetinostat will be given at different doses to find out what effects, if any, they have on treating your cancer and side effects.